Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-NY-ESO-1 TCR CD62L+ T cells in Melanoma
NCT02062359Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Feb 2014
- Primary completion
- Feb 2016
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-NY-ESO-1 T-cell receptor CD62L+ T cells in melanoma, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 3 months. Started Feb 2014; status: terminated.
02
Drugs
anti-NY-ESO-1 T-cell receptor CD62L+ T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02062359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02062359.